News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News AbbVie takes aim at Gilead and BMS with 8-week hep C treatme... Trial backs patient-friendly regime in tough to treat strain.
Gilead Wales experts back HIV prophlyaxis, ahead of key meetings Cost-effectiveness bodies in Wales and Scotland to decide on Truvada in April.
News Pfizer under investigation over links with charities US authorities probing several other drugmakers amid pricing row.
News Is BMS the next pharma takeover target? Speculation mounting that Pfizer and others could try for $90 bn plus merger
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
